English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/173947
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorFuente, José de la-
dc.contributor.authorGortázar, Christian-
dc.contributor.authorJuste, Ramón A.-
dc.date.accessioned2019-01-11T09:58:34Z-
dc.date.available2019-01-11T09:58:34Z-
dc.date.issued2016-
dc.identifierdoi: 10.1586/14760584.2016.1125294-
dc.identifiere-issn: 1744-8395-
dc.identifierissn: 1476-0584-
dc.identifier.citationExpert Review of Vaccines 15(3): 275-277 (2016)-
dc.identifier.urihttp://hdl.handle.net/10261/173947-
dc.description.abstractVaccines are critical for the control of tuberculosis (TB) affecting humans and animals worldwide. First-generation vaccines protect from active TB but new vaccines are required to protect against pulmonary disease and infection. Recent advances in post-genomics technologies have allowed the characterization of host-pathogen interactions to discover new protective antigens and mechanisms to develop more effective vaccines against TB. Studies in the wild boar model resulted in the identification of complement component 3 (C3) as a natural correlate of protection against TB. Oral immunization with heat-inactivated mycobacteria protected wild boar against TB and showed that C3 plays a central role in protection. These results point at C3 as a target to develop novel vaccine formulations for more effective protection against TB in humans and animals.-
dc.description.sponsorshipFunding for TB research was obtained from grants AGL2014-56305 (Ministry of Economy, Spain and FEDER) and European Union FP7 WildTBvac No. 613779.-
dc.publisherTaylor & Francis-
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/613779-
dc.relationMINECO/ICTI2013-2016/AGL2014-56305-C3-1-R-
dc.rightsclosedAccess-
dc.subjectMycobacteria-
dc.subjectVaccine-
dc.subjectImmunology-
dc.subjectComplement-
dc.subjectTuberculosis-
dc.titleComplement component 3: a new paradigm in tuberculosis vaccine-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.1586/14760584.2016.1125294-
dc.date.updated2019-01-11T09:58:34Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderEuropean Commission-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.pmid26605515-
Appears in Collections:(IREC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.